All articles

How Pencil chose its first program before its raise

Sleuth provides a confidence score for every value, so you know which to trust and which to review. Pencil Biosciences, a seed-stage gene-editing company, could potentially aim its platform at many diseases. With a raise coming up, it needed to select one lead program it could defend to investors.

November 13, 2026

Download the full case study

Sleuth’s analysts screened about 11,700 diseases on Pencil’s criteria down to the 150+ that fit the platform, and Dr. John Lambourne, Pencil’s gene editing lead, picked 46 for a deeper look. Sleuth gathered detailed evidence on each, grouped them by fit, and scored confidence in every data point. John reviewed the low scores and compared his options before the lead went to Pencil’s board.

Put your expertise where it counts

640 squares, one per value in the analysis of 46 diseases, with 94 marked for review and 546 used as they were.
One square per value: the 640 in Sleuth’s deeper analysis of the 46 diseases John chose. John checked the 94 scored 1 or 2 and trusted the other 546 as they were.

John used confidence scores to trust the data and narrow the shortlist

Narrowing 150 diseases to a few dozen only works if you trust the numbers your cuts are based on. Sleuth’s analysts built Pencil’s shortlist on Pencil’s criteria, with a confidence score on every estimate of a disease’s patient population. John trusted the well-supported ones, weighed the precision of the estimates on the rest, and used his expertise to pick 46 for deeper analysis.

The narrowing from about 11,700 diseases to one lead, and a shortlist row opened to show two sources that disagree on a patient count.
Illustrative data, not Pencil’s numbers.

Sleuth’s analysts went deeper on John’s shortlist

For each of the 46 diseases on the shortlist, Sleuth’s analysts added 14 measures in four areas, scored every value, and grouped the diseases by fit, so John could compare them side by side and choose his lead.

Pencil’s lead went to its board on data John trusted

A diligent board will ask why one disease was selected over the others. John chose Pencil’s lead from Sleuth’s deep analysis of his shortlist. Every value behind the recommendation had a score, and he had reviewed the ones that needed it. Three days later, Sleuth’s analysts had a full landscape on the lead: competitors, deals, financings, unmet need, and the market.

A lead program’s record with a confidence score on every value.
Illustrative data, not Pencil’s numbers.

See what your team has been missing